Cited by 59Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

In vivo imaging reveals sigmoidal growth kinetic of β-amyloid plaques

Open access
Burgold, Steffen, Filser, Severin, Dorostkar, Mario M, Schmidt, Boris, Herms, Jochen·2014·Acta Neuropathologica Communications

Abstract

A major neuropathological hallmark of Alzheimer's disease is the deposition of amyloid plaques in the brains of affected individuals. Amyloid plaques mainly consist of fibrillar β-amyloid, which is a cleavage product of the amyloid precursor protein. The amyloid-cascade-hypothesis postulates Aβ accumulation as the central event in initiating a toxic cascade leading to Alzheimer's disease pathology and, ultimately, loss of cognitive function. We studied the kinetics of β-amyloid deposition in Tg2576 mice, which overexpress human amyloid precursor protein with the Swedish mutation. Utilizing long-term two-photon imaging we were able to observe the entire kinetics of plaque growth in vivo. Essentially, we observed that plaque growth follows a sigmoid-shaped curve comprising a cubic growth phase, followed by saturation. In contrast, plaque density kinetics exhibited an asymptotic progression. Taking into account the fact that a critical concentration of Aβ is required to seed new plaques, we can propose the following kinetic model of β-amyloid deposition in vivo. In the early cubic phase, plaque growth is not limited by Aβ concentration and plaque density increases very fast. During the transition phase, plaque density stabilizes whereas plaque volume increases strongly reflecting a robust growth of the plaques. In the late asymptotic phase, Aβ peptide production becomes rate-limiting for plaque growth. In conclusion, the present study offers a direct link between in vitro and in vivo studies facilitating the translation of Aβ-lowering strategies from laboratory models to patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2051-5960-2-30

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 52 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Burgold, S., Filser, S., Dorostkar, M. M., Schmidt, B., & Herms, J.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • Technische Universität Darmstadt (DE)
Corresponding author
Herms, Jochen
Venue
Acta Neuropathologica Communications
Published
2014-03-28
Volume
2
Issue
1
Pages
30-30
ISSN
2051-5960 (ISSN-L)
OpenAlex
W2136953158
Cited by
59
References
52
Citations by year
2026: 5 · 2025: 4 · 2024: 8 · 2023: 3 · 2022: 3 · 2021: 6 · 2020: 4 · 2019: 6 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 2 · 2014: 1
FWCI
3.32
Type
journal article
Language
en
Open access
Locations
  • Acta Neuropathologica Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
  • DZNE Pub (submittedVersion, other-oa)
Funders
  • European Commission (Neuro.GSK3, 223276)
  • Deutsche Forschungsgemeinschaft (SFB 596)
  • Bundesministerium für Bildung und Forschung (01GZ0713)
  • Bundesministerium für Wirtschaft und Technologie (16IN0675)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid plaques, Alzheimer's disease, sigmoidal growth curve, plaque progression, plaque density, Tg2576 mice, amyloid precursor protein, amyloid hypothesis, in vivo two-photon imaging, kinetic model, amyloid seeding
MeSH terms
Alzheimer Disease, Animals, Disease Models, Animal, Female, Humans, Kinetics, Male, Mice, Transgenic, Mutation, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Plaque, Amyloid, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review